Eli Lilly And Co (NYSE:LLY) Major Shareholder Sells $29,873,800.00 in Stock

Eli Lilly And Co (NYSE:LLY) major shareholder Lilly Endowment Inc sold 220,000 shares of the firm’s stock in a transaction on Thursday, January 9th. The shares were sold at an average price of $135.79, for a total transaction of $29,873,800.00. Following the completion of the transaction, the insider now owns 114,136,224 shares in the company, valued at $15,498,557,856.96. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Large shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Lilly Endowment Inc also recently made the following trade(s):

  • On Tuesday, January 7th, Lilly Endowment Inc sold 32,645 shares of Eli Lilly And Co stock. The shares were sold at an average price of $132.90, for a total transaction of $4,338,520.50.
  • On Friday, December 20th, Lilly Endowment Inc sold 19,705 shares of Eli Lilly And Co stock. The shares were sold at an average price of $132.90, for a total transaction of $2,618,794.50.
  • On Tuesday, December 17th, Lilly Endowment Inc sold 215,000 shares of Eli Lilly And Co stock. The shares were sold at an average price of $125.69, for a total transaction of $27,023,350.00.
  • On Monday, December 9th, Lilly Endowment Inc sold 10,962 shares of Eli Lilly And Co stock. The shares were sold at an average price of $119.70, for a total transaction of $1,312,151.40.
  • On Friday, December 6th, Lilly Endowment Inc sold 194,038 shares of Eli Lilly And Co stock. The shares were sold at an average price of $120.15, for a total transaction of $23,313,665.70.
  • On Wednesday, December 4th, Lilly Endowment Inc sold 210,000 shares of Eli Lilly And Co stock. The shares were sold at an average price of $119.77, for a total transaction of $25,151,700.00.
  • On Wednesday, November 27th, Lilly Endowment Inc sold 48,953 shares of Eli Lilly And Co stock. The shares were sold at an average price of $117.51, for a total transaction of $5,752,467.03.
  • On Monday, November 25th, Lilly Endowment Inc sold 109,318 shares of Eli Lilly And Co stock. The shares were sold at an average price of $117.60, for a total transaction of $12,855,796.80.
  • On Thursday, November 21st, Lilly Endowment Inc sold 108,264 shares of Eli Lilly And Co stock. The shares were sold at an average price of $115.14, for a total transaction of $12,465,516.96.
  • On Monday, November 18th, Lilly Endowment Inc sold 10,598 shares of Eli Lilly And Co stock. The shares were sold at an average price of $114.00, for a total transaction of $1,208,172.00.

Shares of NYSE:LLY traded up $1.82 during midday trading on Friday, reaching $137.74. 308,055 shares of the company’s stock were exchanged, compared to its average volume of 3,124,141. The company’s 50 day simple moving average is $124.92 and its two-hundred day simple moving average is $114.67. The firm has a market capitalization of $128.38 billion, a PE ratio of 24.88, a price-to-earnings-growth ratio of 1.75 and a beta of 0.20. Eli Lilly And Co has a 12 month low of $101.36 and a 12 month high of $137.00. The company has a debt-to-equity ratio of 4.09, a quick ratio of 0.88 and a current ratio of 1.17.

Eli Lilly And Co (NYSE:LLY) last released its quarterly earnings data on Wednesday, October 23rd. The company reported $1.48 EPS for the quarter, topping analysts’ consensus estimates of $1.43 by $0.05. The company had revenue of $5.48 billion during the quarter, compared to the consensus estimate of $5.50 billion. Eli Lilly And Co had a net margin of 35.10% and a return on equity of 107.99%. The firm’s revenue for the quarter was up 3.2% compared to the same quarter last year. During the same period last year, the firm earned $1.39 EPS. On average, research analysts anticipate that Eli Lilly And Co will post 5.8 earnings per share for the current year.

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 10th. Stockholders of record on Friday, February 14th will be issued a dividend of $0.74 per share. This represents a $2.96 dividend on an annualized basis and a dividend yield of 2.15%. This is an increase from Eli Lilly And Co’s previous quarterly dividend of $0.65. The ex-dividend date is Thursday, February 13th. Eli Lilly And Co’s dividend payout ratio (DPR) is presently 46.49%.

Large investors have recently added to or reduced their stakes in the company. Investors Research Corp lifted its stake in Eli Lilly And Co by 5.6% in the third quarter. Investors Research Corp now owns 1,764 shares of the company’s stock valued at $197,000 after buying an additional 93 shares in the last quarter. Global Wealth Management Investment Advisory Inc. lifted its stake in Eli Lilly And Co by 10.2% in the second quarter. Global Wealth Management Investment Advisory Inc. now owns 1,023 shares of the company’s stock valued at $113,000 after buying an additional 95 shares in the last quarter. FTB Advisors Inc. lifted its stake in Eli Lilly And Co by 3.0% in the third quarter. FTB Advisors Inc. now owns 3,275 shares of the company’s stock valued at $366,000 after buying an additional 95 shares in the last quarter. Carnegie Capital Asset Management LLC lifted its stake in Eli Lilly And Co by 1.9% in the third quarter. Carnegie Capital Asset Management LLC now owns 5,228 shares of the company’s stock valued at $585,000 after buying an additional 97 shares in the last quarter. Finally, Investors Asset Management of Georgia Inc. GA ADV lifted its stake in Eli Lilly And Co by 0.7% in the third quarter. Investors Asset Management of Georgia Inc. GA ADV now owns 14,035 shares of the company’s stock valued at $1,570,000 after buying an additional 100 shares in the last quarter. 76.46% of the stock is owned by institutional investors.

A number of brokerages have weighed in on LLY. Bank of America began coverage on shares of Eli Lilly And Co in a report on Wednesday, October 16th. They issued a “buy” rating and a $133.00 price target for the company. Morgan Stanley raised shares of Eli Lilly And Co from an “equal weight” rating to an “overweight” rating and increased their price target for the company from $116.00 to $150.00 in a report on Wednesday, December 18th. They noted that the move was a valuation call. Argus increased their price target on shares of Eli Lilly And Co from $145.00 to $165.00 and gave the company a “buy” rating in a report on Monday, December 30th. UBS Group reduced their price target on shares of Eli Lilly And Co from $134.00 to $133.00 and set a “buy” rating for the company in a report on Thursday, October 17th. Finally, TheStreet raised shares of Eli Lilly And Co from a “c+” rating to a “b-” rating in a report on Friday, November 8th. Five equities research analysts have rated the stock with a hold rating and ten have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus target price of $135.67.

Eli Lilly And Co Company Profile

Eli Lilly and Company discovers, develops, manufactures, and markets pharmaceutical products worldwide. The company operates in two segments, Human Pharmaceutical Products and Animal Health Products. It offers endocrinology products for the treatment of diabetes; osteoporosis in postmenopausal women and men; and human growth hormone deficiency and pediatric growth conditions.

Recommended Story: Outstanding Shares, Buying and Selling Stocks

Insider Buying and Selling by Quarter for Eli Lilly And Co (NYSE:LLY)

Receive News & Ratings for Eli Lilly And Co Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly And Co and related companies with MarketBeat.com's FREE daily email newsletter.